This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 1993:60:666-71.

MAO-B inhibitors in Parkinson's disease

C W Olanow¹

Affiliations

PMID: 8420207

Review

MAO-B inhibitors in Parkinson's disease

C W Olanow. Adv Neurol. 1993.

. 1993:60:666-71.

Author

C W Olanow¹

Affiliation

¹ Department of Neurology, University of South Florida, Tampa 33606.

PMID: 8420207

No abstract available

PubMed Disclaimer

Similar articles

MAO-B inhibitors for the treatment of Parkinson's disease.
[No authors listed] [No authors listed] Mov Disord. 2002;17 Suppl 4:S38-44. doi: 10.1002/mds.5559. Mov Disord. 2002. PMID: 12211138 Review. No abstract available.
MAO type B inhibitors as adjunct to L-dopa therapy.
Youdim MB, Finberg JP. Youdim MB, et al. Adv Neurol. 1987;45:127-36. Adv Neurol. 1987. PMID: 3103383 No abstract available.
Monoamine oxidase inhibitors--is it time to up the TEMPO?
Rascol O. Rascol O. Lancet Neurol. 2003 Mar;2(3):142-3. doi: 10.1016/s1474-4422(03)00318-1. Lancet Neurol. 2003. PMID: 12849233 No abstract available.
Critical role of MAO inhibition in Parkinson's disease.
Knoll J. Knoll J. Adv Neurol. 1987;45:107-10. Adv Neurol. 1987. PMID: 3103382 No abstract available.
Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors.
Henchcliffe C, Schumacher HC, Burgut FT. Henchcliffe C, et al. Expert Rev Neurother. 2005 Nov;5(6):811-21. doi: 10.1586/14737175.5.6.811. Expert Rev Neurother. 2005. PMID: 16274338 Review.

See all similar articles

Cited by

Inhibitory Activity of N- and S-Functionalized Monoterpene Diols Towards Monoamine Oxidases A and B.
Podturkina AV, Ardashov OV, Soldatova YV, Poletaeva DA, Smolina AV, Vasyuchenko EP, Vyatkin YV, Li-Zhulanov NS, Faingold II, Salakhutdinov NF, Volcho KP. Podturkina AV, et al. Int J Mol Sci. 2024 Dec 26;26(1):97. doi: 10.3390/ijms26010097. Int J Mol Sci. 2024. PMID: 39795958 Free PMC article.
Neuropharmacology of dopamine receptors:: Implications in neuropsychiatric diseases.
Tarazi FI. Tarazi FI. J Sci Res Med Sci. 2001 Oct;3(2):93-104. J Sci Res Med Sci. 2001. PMID: 24019715 Free PMC article.
Comparison of Selegiline and Rasagiline Therapies in Parkinson Disease: A Real-life Study.
Peretz C, Segev H, Rozani V, Gurevich T, El-Ad B, Tsamir J, Giladi N. Peretz C, et al. Clin Neuropharmacol. 2016 Sep-Oct;39(5):227-31. doi: 10.1097/WNF.0000000000000167. Clin Neuropharmacol. 2016. PMID: 27438181 Free PMC article.
Medical management of Parkinson's disease.
Goldenberg MM. Goldenberg MM. P T. 2008 Oct;33(10):590-606. P T. 2008. PMID: 19750042 Free PMC article. No abstract available.
Adenosine A(2A) Receptor Antagonists and Parkinson's Disease.
Shook BC, Jackson PF. Shook BC, et al. ACS Chem Neurosci. 2011 Oct 19;2(10):555-67. doi: 10.1021/cn2000537. Epub 2011 Jun 21. ACS Chem Neurosci. 2011. PMID: 22860156 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Medical
- MedlinePlus Health Information